How Has the Non Small Cell Lung Cancer NSCLC Market Size Evolved in Recent Years?
The non small cell lung cancer nsclc market has seen considerable growth due to a variety of factors.
• In recent years, the market size for non-small cell lung cancer (NSCLC) has seen rapid expansion. The growth, set to increase from $20.1 billion in 2024 to $22.35 billion in 2025, registers a compound annual growth rate (CAGR) of 11.1%.
Various factors responsible for the growth in the past include the development of immunotherapy, expansion of clinical trials, and initiatives to stop smoking, along with the advancement in genomic profiling and precision medicine.
What Are The Predictions for The Non Small Cell Lung Cancer NSCLC Market in the Coming Years?
The non small cell lung cancer nsclc market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations reveal that the market size for non-small cell lung cancer (NSCLC) is on the verge of robust expansion in the coming years, expected to surge to $33.29 billion by 2029, with a compound annual growth rate (CAGR) of 10.5%.
The growth anticipated in the forecast period can be pegged on the advent of combination therapies, the assimilation of artificial intelligence (AI), the development of personalized vaccines, collective global research efforts, and a focus on patient-centric care. Also, the forecast period will be characterized by significant trends, such as the incorporation of telemedicine in oncology, upcoming liquid biopsy technologies, improvements in diagnostic technology, the implementation of minimally invasive surgical approaches, and the use of immune checkpoint inhibitors.
Which Drivers Are Accelerating Growth In The Non Small Cell Lung Cancer NSCLC Market?
The non-small cell lung cancer (NSCLC) market's growth is predicted to be bolstered by growing tobacco use. Tobacco use is characterized by the personal consumption of tobacco goods in various forms - smoking, chewing, or snuffing - introducing nicotine and other chemicals into the human system. These tobacco-derived carcinogens can harm the DNA in lung cells, causing mutations and uncontrolled proliferation of cancerous cells, including NSCLC. According to the 2024 National Youth Tobacco Survey released by the US Food and Drug Administration in October 2024, roughly 2.25 million students (1.1%) currently use tobacco. This includes about 1.58 million high school students (10.1%) and around 640,000 middle school students (5.4%), with about 760,000 students (2.8%) currently using any combustible tobacco product and approximately 840,000 (3.0%) using multiple tobacco products. Hence, the growing tobacco consumption rate is steering the expansion of the non-small cell lung cancer (NSCLC) market. The proliferation of the non-small cell lung cancer (NSCLC) market is projected to be further fueled by escalating levels of air pollution. Air pollution involves detrimental substances, primarily in the form of gases or particles present in the Earth's atmosphere, eliciting adverse health impacts. These pollutants can boost the risk of NSCLC by inducing inflammation, DNA damage, and mutations in lung cells, giving rise to cancerous tumors. For instance, the World Health Organization, in June 2023, linked air and household pollution to about 7 million early deaths each year. In addition, nearly 2.4 billion individuals are exposed to hazardous household air pollution levels while using contaminating open fires for cooking, powered by kerosene, biomass, and coal. Furthermore, the World Bank, a US-based financial institution, predicted in September 2022 that health damage caused by air pollution would approximate $8.1 trillion annually, equivalent to 6.1% of global GDP. Consequently, the surge in air pollution levels is poised to accelerate the growth of the non-small cell lung cancer (NSCLC) market.
What Are The Core Segments Of The Global Non Small Cell Lung Cancer NSCLC Market?
The non-small cell lung cancer (NSCLC) market covered in this report is segmented –
1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma
Pre-Book The Non Small Cell Lung Cancer NSCLC Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Non Small Cell Lung Cancer NSCLC Market?
Leading companies in the non-small cell lung cancer (NSCLC) market are concentrating on the development of a variety of treatment alternatives, including monotherapy interventions, to establish a competitive advantage. The concept of monotherapy treatment refers to the utilization of a single medication or therapeutic approach for treating a medical condition or disorder, as opposed to using a combination of different strategies. For example, in June 2022, the European Commission, a Belgium-based regulatory body, granted approval to Novartis AG, a Swiss pharmaceutical company, for the use of Tabrecta (capmatinib) in the treatment of adult patients with advanced non-small cell lung cancer exhibiting METex14 skipping. This drug provides a new targeted treatment option for those patients in Europe who have previously undergone treatments and are suffering from advanced NSCLC with METex14 skipping-causing mutations. This is currently the most favored targeted therapy for advanced NSCLC with METex14 skipping-causing alterations.
Who Are the Key Players In The Non Small Cell Lung Cancer NSCLC Market?
Major companies operating in the non-small cell lung cancer (NSCLC) market report are:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• UCB S.A.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Cipla Limited
• Ferring B.V.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC
• Zydus Lifesciences Ltd.
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Almirall S.A.
• Clovis Oncology
• Revolution Medicines
What Are The Regional Insights Into The Non Small Cell Lung Cancer NSCLC Market?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
